IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for, Diabetes Res Clin Pract, vol.128, pp.40-50, 2015. ,
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, vol.339, issue.4, pp.229-263, 1998. ,
Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med, vol.358, issue.6, pp.580-91, 2008. ,
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, vol.2016, pp.957-67, 10022. ,
,
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial, Eur Heart J, vol.37, issue.19, pp.1526-1560, 2016. ,
,
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus, JACC Heart Fail, vol.6, issue.10, pp.813-822, 2018. ,
Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study, Bmj, vol.344, p.8059, 2012. ,
,
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N Engl J Med, vol.376, issue.18, pp.1713-1722, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01896445
Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges, Eur Heart J, 2016. ,
Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation, BMJ Open, vol.4, issue.6, p.4301, 2014. ,
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies, Eur Heart J, vol.34, issue.19, pp.1404-1417, 2013. ,
Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure, Eur J Heart Fail, 2017. ,
,
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus, J Am Heart Assoc, vol.2017, issue.6, p.6 ,
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes, N Engl J Med, vol.373, issue.7, pp.610-630, 2015. ,
,
Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N Engl J Med, vol.369, issue.14, pp.1327-1362, 2013. ,
,
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, vol.385, issue.9982, pp.2067-76, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01745763
,
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome, Am Heart J, vol.162, issue.4, 2011. ,
,
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial, Diabetes Obes Metab, vol.20, issue.3, pp.654-659, 2018. ,
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial, J Am Heart Assoc, vol.7, issue.20, 2018. ,
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients ,
, Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care), Circulation, vol.2017, issue.20, pp.1911-1921
,
Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives, BMC Med, vol.14, issue.1, p.181, 2016. ,
On the operational characteristics of the Benjamini and Hochberg False Discovery Rate procedure, Stat Appl Genet Mol Biol, vol.6, p.27, 2007. ,
Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis, 2001. ,
Bayesian Case-deletion Model Complexity and Information Criterion, Stat Interface, vol.7, issue.4, pp.531-542, 2014. ,
Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide, Ann Intern Med, vol.160, issue.2, pp.122-153, 2014. ,
A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, vol.94, pp.496-509, 1999. ,
Association of troponin T detected with a 20 highly sensitive assay and cardiac structure and mortality risk in the general population, Jama, vol.2010, issue.22, pp.2503-2515 ,
,
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial, J Am Heart Assoc, vol.2020, issue.1, p.12797 ,
URL : https://hal.archives-ouvertes.fr/hal-02611354
PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol, vol.62, issue.15, pp.1365-72, 2013. ,
,
The structure of the death receptor 4-TNFrelated apoptosis-inducing ligand (DR4-TRAIL) complex, Acta Crystallogr F Struct Biol Commun, vol.71, pp.1273-81, 2015. ,
,
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5, Mol Cell, vol.4, issue.4, pp.563-71, 1999. ,
GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction ,
, Eur J Prev Cardiol, vol.2017, issue.15, pp.1576-1583
Anti-inflammatory therapies for cardiovascular disease, Eur Heart J, vol.35, issue.27, pp.1782-91, 2014. ,
,
, , p.21
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure, Circ Heart Fail, vol.12, issue.5, p.5897, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02267410
Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke, vol.7, p.40994, 2017. ,
,
Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults, JAMA Cardiol, vol.3, issue.4, pp.318-325, 2018. ,
,
FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin, Oncotarget, vol.2016, issue.40, pp.64649-64664 ,
The Effect of AMBP ,
Their Haplotypes, and Gene-Environment Interactions on the Risk of Atherothrombotic Stroke Among the Chinese Population, Genet Test Mol Biomarkers, vol.23, issue.7, pp.487-494, 2019. ,
The Association of Serum hsCRP and Urinary Alpha1-Microglobulin in Patients with Type 2 Diabetes Mellitus, Biomed Res Int, p.6364390, 2019. ,
,
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial, Diabetes Care, vol.41, issue.2, pp.356-363, 2018. ,
,
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebocontrolled trial, Lancet, vol.392, pp.1519-1529, 2018. ,
,
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes, vol.2020, 2019. ,
, Diabetes Care, vol.2020, pp.111-134
Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians, J Am Coll Cardiol, vol.54, issue.14, pp.1209-1236, 2009. ,
, HFH: Clinical model vs. Clinical+BNP+Gal9; MI: Clinical model vs. Clinical+Troponin+FGF23+AMBP; Stroke: Clinical model vs. Clinical+Troponin) and the same clinical variables as described in the Table 1 (Previous HFH, Diabetes duration (per year), Myocardial infarction, eGFR (per ml/min/1.73m2), Stroke, SBP, Hypertension, Atrial fibrillation, CV death/HFH: Clinical model vs. Clinical+BNP+Troponin+TRAILR2
, Figure 1. Multivariable c-index and Bayesian Information Criteria (BIC) for the primary outcome (A) C-index (B) BIC